Nutrigenomica
Nutrigenomica

Nutrigenomics and Pharmacogenomics Genetic Test

€650,00

Sample required: Non-invasive saliva swab · 90-day stability at 8–28 °C ·

Turnaround time: 4–5 weeks

Laboratory standard: ISO 15189 accredited molecular genetics workflow (LDT – Laboratory Developed Tests)

The Nutrigenomics and Pharmacogenomics Genetic Test is the most comprehensive integrated genomic survey for understanding both the body's response to nutrients and supplements, and the metabolization of major drugs. Performed on a saliva swab with an ISO 15189 accredited workflow, it combines metabolic Polygenic Risk Scores (PRS) with the mapping of enzymatic variants responsible for drug efficacy and toxicity. A single, permanent analysis to personalize nutrition, prevention, and pharmacological therapies throughout one's life.

Our genetic makeup influences not only how we assimilate food and nutrients, but also the way our liver and tissues process, activate, and eliminate drugs. This test combines comprehensive nutrigenomic profiling with pharmacogenomics, offering a clear framework for optimizing diet, supplementation, and safety in current and future pharmacological treatments.


Informed consent

artt. 13 e 9 Reg. UE 2016/679 - GDPR

Required

Consent to the processing of health-related data for care purposes (section 3.a).

Required

Consent to receiving the service via teleconsultation, with the limits described in the notice.

Optional

Consent to possible recording of the session (not required for the service).

How does it work?

  • Self-collection: Perform the saliva swab at home.
  • Secure shipping: Send the sample using the included prepaid envelope. No need for refrigerated storage.
  • Molecular analysis and reporting: The laboratory performs sequencing/genotyping and biostatistical processing of metabolic and pharmacogenetic profiles. The complete report will be available online within 4–5 weeks.

Your genetic makeup is immutable; the test is performed only once in a lifetime. 

Why choose?

  • Dual profiling in a single sample: Combine personalized nutritional guidance with pharmacological safety profiling.
  • Lifelong therapeutic safety: Map the genetic variations that influence drug response, providing the physician with a tool to personalize molecules and dosages and avoid unwanted side effects.
  • Integrated Polygenic Risk Scores (PRS): Consider overall combined risk rather than relying on single, isolated variants.
  • Support for chronic therapies and prevention: Useful both for those already taking daily medication and as a guidance map for future treatments.
  • Synergy with the Urobiome and Gut Microbiome: Allows for the cross-referencing of genetic predisposition (fixed) with metabolic response and the microbial environment (modifiable).

Who is it for?

  • Patients on chronic pharmacological therapy or polytherapy: Those who regularly take medications (e.g., for hypertension, cholesterol, anxiety/depression, chronic pain) and wish to optimize their tolerability and effectiveness.
  • Those who have experienced ineffectiveness or adverse effects from medications: Individuals with a history of abnormal reactions to active ingredients or poor response to conventional therapies.
  • People oriented towards primary prevention and longevity: Those who want a complete map of nutrition and pharmacogenomics to keep for any future medical need.
  • Those seeking highly personalized nutritional or sports programs: Individuals who do not see results from standard diets or athletes who want to optimize recovery and performance.

Disclaimer

  • Accreditation and Methodology: Performed according to an ISO 15189 accredited molecular genetics workflow (LDT – Laboratory Developed Tests). 
  • Use of pharmacogenomic data: Pharmacogenetic information is for informational purposes only and is intended to support the attending physician or specialist. No ongoing pharmacological therapy should be suspended, modified, or initiated independently based on the report without the physician's advice. 
  • Predictive value: The results describe predispositions and relative risks, not diagnoses of disease or absolute certainties of drug reaction.